Sidana, Surbhi
Tandon, Nidhi http://orcid.org/0000-0003-4008-9081
Dispenzieri, Angela
Gertz, Morie A.
Buadi, Francis K.
Lacy, Martha Q.
Dingli, David
Fonder, Amie L.
Hayman, Suzanne R.
Hobbs, Miriam A.
Gonsalves, Wilson I.
Warsame, Rahma M.
Kourelis, Taxiarchis
Hwa, Yi Lisa
Kapoor, Prashant
Kyle, Robert A.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Rajkumar, S. Vincent
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Article History
Received: 23 May 2018
Revised: 28 August 2018
Accepted: 3 September 2018
First Online: 15 October 2018
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest directly related to this work. Below is a list of all financial disclosures for authors: SS: Honoraria for advisory board, Janssen AD: Research Funding from Celgene, Takeda, Prothena, Jannsen, Pfizer, Alnylam, GSKPK: Research Funding from Celgene, Takeda MQL: Research Funding from Celgene MAG: Honoraria/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Specytrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physcians Education Resource and Teva; SKK: Research Funding and membership on an entity’s Board of Directors or advisory committees: AbbVie, Celgene, Janssen, KITE, Merck. Membership on an entity's Board of Directors or advisory committees: Oncopeptides, Takeda. Research funding from Novartis and Roche.